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p16INK4 and RB1 are two potent cell cycle regulators to control the G1/S transition by interacting with CDK4/6, E2F, and D-type
cyclins, respectively. Depending on the tumour type, genetic alterations resulting in the functional inactivation have frequently
been reported in both genes. By contrast, much less is known regarding the overexpression of these proteins in the tumor cells.
In this study, expressions of p16INK4 RB1, and CDKN2A copy number variances (CNV) in the tumor cells were assessed by
immunohistochemistry and ﬂuorescence in situ hybridization (FISH), respectively, in 73 nonsmall cell lung cancer (NSCLC) with
known 5-year survivals. The histologic type (P = 0.01), p16INK4 (P = 0.004), and RB1 (P<0.001) were predictive of survivals.
The CDKN2A CNV (P<0.05) was also signiﬁcant when compared to those cases without CNV. Therefore, among the molecular
geneticprognosticfactors,expressionsofRB1andp16INK4 inthetumorcellswerethemoststronglypredictiveofadverseoutcomes
in stage I and II nonsquamous NSCLC.
1.Introduction
Primary lung carcinoma is one of the leading causes of
cancer death worldwide. Genetic and molecular alterations
involving tumorigenesis have been extensively studied. Inac-
tivation of tumor suppressor genes by deletion, mutations,
altered splicing, promoter mutations, or epigenetic mod-
iﬁcations are the common causes in lung cancers [1–3].
Ampliﬁcation and activation mutations of oncogenes are
often account for many malignant behaviors and worse
clinical outcomes [4, 5]. In fact, most of these genetic
alterations might directly or indirectly aﬀect the cell cycle
and proliferation of the tumor cells. p16INK4 and RB1 are
two important tumor suppressor proteins and participate in
negatively regulating the proliferation of normal cells [6–
8]. Like other tumors, studies were focused on the genetic
alterations resulting in either loss or decreased expressions
and functions in the tumor cells because of their inhibitory
roles in cell proliferation [9–14]. By contrast, studies were
limited regarding the overexpression of these proteins and
theireﬀectsonthetumorigenesisandprognosisinthetumor
cells. Reports become more prominent in the head and neck
squamous carcinomas in which p16INK4 was overexpressed
under the viral eﬀect by the high-risk serotypes of the
human papilloma virus (HPV), though sparse reports in
tumors like basal-like breast carcinoma and NSCLC [15–17].
A single study showed that the combined RB-negative/p16-
positive/cyclin D1-negative tumors in NSCLC might relate
to the adverse outcomes, but the independent role of each
proteins (p16INK4 and RB1) in the unfavorable prognosis
was not conﬁrmed [17]. In this paper, we studied p16INK4
and RB1 protein expressions and CDKN2A gene copy
variances in NSCLC with special reference to an association
of the abnormal individual protein expression with clinical
characters.
2.MaterialsandMethods
2.1. Case Selections and Tissue Microarray. At i s s u e
microarray (TMA) was prepared from formalin-ﬁxed2 Journal of Oncology
paraﬃn-embedded (FFPE) tissue specimens from 1985
to 1997 acquired through the pathology archive services
of the Ohio State University Medical Center, Columbus,
OH, USA. All the cases selected for this study meet
following criteria: (1) nonsquamous NSCLC, surgically
managed patients with stage I or stage II NSCLC at the
time of diagnosis; (2) available clinical followup and
outcome data; (3) adequate tissue (all surgical resection
specimen) for immunohistochemical stains (IHC) or
molecular studies. Patients selected for this study received no
neoadjuvant chemotherapy or radiotherapy prior to surgery.
Seventy-three NSCLC cases met the criteria and were
included in this study. All the cases were reviewed, and the
pathology diagnosis of each case was reclassiﬁed according
to the current WHO classiﬁcation. The study has been
approved by the institutional human research committee.
Additionally, tissues from human brain, lung, lymph node,
kidney, placenta, thyroid, heart, liver, testes, and adrenal
glands (1-2 samples each) were included in the TMA as
normal controls.
2.2. Immunohistochemistry (IHC). Immunohistochemistry
wasdoneusingmonoclonalp16antibodycloneINK4(MTM
laboratories)orpRBclone13A10(NovoCastraLaboratories)
on a DAKO-automated staining instrument (Dako Scientiﬁc
Systems, Tucson, AZ, USA) using an ABC-based detection
kit (I View DAB, Ventana Medical Systems) or polymer-
based detection kit (Mach3, Biocare Medical) as described
previously [18, 19]. Staining intensity was scored semiquan-
titatively separately for the cytoplasm and/or nucleus, using
a scale from 0 to 3: 0, no staining; 1+, weak intensity in
more than 25% of nuclei; 2+ moderate and 3+, strongly
positive intensity in more than 75% of nuclei. Tumor cells
with moderate (2+) or strong (3+) stainings were graded
as overexpression or positive, while none (0) and weak
(1+) stainings were negative. Specimens were scored in a
blinded fashion by two pathologists (W. Zhao and M. E.
Leon).
2.3. Interphase Fluorescence In Situ Hybridization (FISH).
To investigate the CDKN2A gene copy number variances
(CNV), a dual color chromosome 9 centromere, CEP9
(spectrum green), and CDKN2A gene spectrum (orange)
probekitwereused(Vysis,AbbottLaboratories,AbbottPark,
IL) on the paraﬃn-embedded tissues (FFPE), either on the
TMA or full sections at 2 to 4-μm-thickness as described
previously with modiﬁcations [19]. Normally, each nucleus
w a se x p e c t e dt oh a v e2c o p i e so fe a c hCEP9 (reference
numbers of chromosome 9) andCDKN2Agene,thatis,acell
without CNV should have ratio of 1 (2 CDKN2A/2 CEP9).
T h el o s so fCDKN2A might be homozygous (0/2, ratio = 0)
or heterozygous (1/2, ratio = 0.5). The gains of CDKN2A
might be ampliﬁcation (>4/2, ratio >2.1) or polysomy
9( b o t hCDKN2A and CEP9 were ampliﬁed). All of the
images and FISH slides were reviewed by a pathologist (W.
Zhao) using a ﬂuorescence microscope (Olympus BX51),
and images were taken with a digital image camera (DP70,
Olympus, USA).
2.4. In Situ Hybridization of HPV High- and Low-Risk Probes.
The sample was processed and detected for HPV-H and -L
risk probes as described previously [20].
2.5. Survival and Statistical Analysis. Patient survival status
at ﬁve years (60 months) after initial pathologic diagnosis
was obtained from the institutional information warehouse
at The Ohio State University and used as the outcome
variable to calculate the ﬁve-year overall survival rate. Uni-
variable analyses were performed using Chi-square (χ2)t e s t
or Fisher’s exact test to study the associations of categorical
variables to the outcomes. P value of <0.05 was considered
statistically signiﬁcant. Statistical analyses were performed
using MedCalc software (Frank Schoonjans, Mariakerke,
Belgium).
3. Results
A total 73 cases of nonsquamous NSCLC at stage I and II
were enrolled in this study. Overall, 32 out of 73 (43.8%)
patients survived more than 5 years after the diagnosis. The
factorswithnocorrelationtotheoutcomeswereage(median
65.0 years, 34–85) and gender (males: 57.5% versus females:
42.5%).
Histologically, there were 51 adenocarcinoma, 9 large cell
carcinoma, 8 large cell neuroendocrine carcinoma, and 5
mucoepidermoid tumors, and they were grouped into two
categories, adenocarcinomas (51, 69.9%), and nonadenocar-
cinoma(22,30.1%).Thepatientswithadenocarcinomalived
longer than those with nonadenocarcinomas (52.9% versus
22.7%, P = 0.01).
Immunohistochemical stains for p16INK4 and RB1 were
performed on all samples (n = 73). The prevalence of
p16INK4-positivity was 30.1% (22/73). The representative
IHC results were shown in Figure 1.I tw a sp r e s e n tb o t h
in cell nucleus and cytoplasm, and ranged from strong to
moderate(Figures1(a)and1(b)).Thenegativecases(69.9%)
included both 1+ (n = 6) (Figure 1(c))a n d0( n = 45)
(Figures 1(d) and 1(e)) expressions. The proteins were not
detected in the normal lung tissues (Figure 1(f)) or the
tumor stromas (Figures 1(a)–1(c)). The p16INK4-positive
rates between adenocarcinomas and nonadenocarcinoma
were not statistically signiﬁcant (31.9% versus 26.9%, P>
0.05).
The presence of p16INK4 in the tumor cells was associated
with unfavorable outcomes (RR: 1.8142, 95% CI: 1.2642–
2.6037, P = 0.004) (Table 1). Among the survived subjects,
the positive rate was 12.5% (4/32). In contract, among the
dead subjects, it was 43.9% (18/41), a 3.5-fold higher than
the survived group. Although being adenocarcinoma was a
favorable factor, cases with p16INK4-positive adenocarcino-
mas were signiﬁcantly predictive of shorter survivals (RR:
2.0,95%CI:1.155–3.4623,P = 0.035)thanthenegativeones
(Table 1). Their relationship in nonadenocarcinoma tumors
was not done due to the low numbers.
A relationship between p16INK4 IHC and CNV of
CDKN2A assessed by FISH was studied. Figure 2 illustrated
representative cases with ampliﬁcation (Figure 2(a))a n dJournal of Oncology 3
(a) (b) (c)
(d) (e) (f)
Figure 1: p16INK4 immunohistochemical staining in lung cancer samples. The patterns in tumor cells range from strong (3+) in an
adenocarcinoma with acinar diﬀerentiation, moderate (2+) in a mixed adenocarcinoma, and weak (1+) in a mixed adenocarcinoma from
( a )t o( c ) ,r e s p e c t i v e l y .N o( 0 )e x p r e s s i o nw a ss e e ni nt u m o rc e l l sf rom a large cell neuroendocrine carcinoma (d) and an adenocarcinoma
with acinar diﬀerentiation (e-f). There is no expression in normal lung tissue (f) or stromal including normal lymphocytes of the the tumor
samples (a–e).
Table 1: Comparison of p16, histology, FISH, and ﬁve-year survival rate1.
p16 IHC
Overall∗ Adenocarcinoma∗∗ Nonadenocarcinoma∗∗∗ CNV CDKN2A∗∗∗
Alive Dead Alive Dead Alive Dead Gain
(ratio > 2)
Loss
(ratio = 0)
Loss
(ratio = 0.5)
Normal
(ratio = 1)
Positive 4 (12.5) 18 (43.9) 5 (18.5) 12 (50.0) 0 (0.0) 5 (29.4) 7 (77.8) 0 (0.0) 3 (33.3) 12 (10.0)
Negative 28 (87.5) 23 (56.1) 22 (81.5) 12 (50.0) 5 (100.0) 12 (70.6) 2 (22.2) 5 (100) 6 (66.7) 35 (90.0)
1The data presented in the table in format of “case number (% of the same column)”.
Fisher’s probability exact test (two tailed): ∗P = 0.004, ∗∗P = 0.036, ∗∗∗not done.
(a) (b)
Figure 2: Gene copy variances of CDKN2A evaluated by FISH. (a) Representative example of tumor cells with increased CDKN2A gene
copy numbers: the multiple red CDKN2A signals with fewer green CEP9 signals indicate the ampliﬁcation (ratio >2.1). (b). Representative
example of tumor cells with homozygous loss: the two or multiple green CEP9 signals but absent of red CDKN2A signals in tumor cells
indicate speciﬁc loss of this gene rather than total loss of chromosome 9 (ratio = 0 ) .N o t eap o s s i b l es t r o m a lc e l lw i t han o r m a ls i g n a lp a t t e r n
(2 red and 2 green) at the lower right corner of (b).4 Journal of Oncology
Table 2: Correlation of CDKN2A copy number variances with the outcome and the tumor types1.
CDKN2A CPN
Survival∗ Histologic type∗∗
Alive Dead Adenocarcinoma Nonadenocarcinoma
CNV 6 (18.8)∗ 17 (41.5) 14 (27.5) 9 (40.9)
Normal 26 (81.2) 24 (58.5) 37 (72.7) 13 (49.1)
1The data presented in the table in format of “case number (% of the same column)”.
Fisher’s probability exact test (two tailed): ∗P = 0.0455 and ∗∗P = 0.282.
(a) (b) (c)
(d) (e) (f)
Figure 3: RB1 immunohistochemical staining in lung cancer samples. The represesntative patterns of expression range from strong (3+) in
a mixed adenocarcinoma (a), a large cell neuroendocrine carcinoma (b), moderate (2+) in a large cell neuroendocrine carcinoma (c), and
weak (1+) in an adenocarcinoma with acinar diﬀerentiation, respectively, in the nuclei of tum o rc e l l s .N o( 0 )e x p r e s s i o nw a ss e e ni nt u m o r
cells of an mixed adenocarcinoma (e). However, weak expression (1+) is present in normal lung tissue (f) or stroma.
homozygous loss (Figure 2(b)), respectively. Of 73 cases
tested, the prevalence of CNV was 31.5% (23/73) which
included both gains (3 ampliﬁcation and 6 polysomy) and
losses(5homozygouslossand9heterozygous)(Table 1).The
IHC results were obviously proportional to the gains (7/9,
77.8%) or homozygous losses (0%, 0/5) of CDKN2A gene
(Table 2).Incaseswithheterozygousloss,6of9(66.7%)were
positive for IHC. In contrast, 18% (9/50) samples without
CNV had positive p16INK4 which reﬂects uncertainty of the
association of IHC and CNV in these two groups. As a result,
only 31.8% (7/22) p16INK4-positive tumors were caused by
the gain of CDKN2A gene.
CDKN2A abnormalities were more often seen in non-
adenocarcinoma than adenocarcinoma, but the diﬀerence
was not statistically signiﬁcant (40.9% versus 27.5%) (P>
0.05). When compared to those with normal CDKN2A gene
copies, the presence of CNV in CDKN2A in the tumors was
associated with the unfavorable outcomes (RR: 1.5399; 95%
CI: 1.056–2.245; P<0.05) (Table 2).
In the head and neck carcinoma, p16INK4 positivity
was positively associated with the infection of the high-risk
human papilloma viruses (HPV) [20]. We examined this
correlation by in situ hybridization (ISH) on the 73 tumor
samples, and none (0/73, 0%) was positively detected with
HPV-H and HPV-L probes (Data not shown).
RB1 expression was readily detected in the nuclei by IHC
ranging from strong (3+ to 2+), weak (1+), to absent, as
illustrated in Figure 3.I nc o n t r a s tt op 1 6 INK4, expression of
RB1 (1+) was detected in the nuclei of the normal control
tissues from heart, lung, thyroid, testes, adrenal gland,
prostate, and kidney but variably in the stromal endothelial,
ﬁbroblast, and lymphoid cells. The expression of low level of
RB1 in the normal tissues might be due to the fact that RB1
promoter are reminiscent which might be associated with
housekeeping genes and result in the ubiquitous expression
of the RB1 gene [21].
Of the 73 cases, 41 were negative (0-1+, 56.2%), 32 were
positive (2 to 3+, 43.8%) for RB1 expression, respectively
(Table 3). The RB1-positive tumors were signiﬁcantly associ-
ated with adverse outcomes (RR: 2.002; 95% CI: 1.309–3.06;
P<0.001) (Table 3), which were independent from other
f a c t o r ss u c ha sa g e ,s e x ,h i s t o l o g i c a ls u b t y p e s ,a n dp 1 6 INK4Journal of Oncology 5
Table 3: Results of RB IHC scores and ﬁve-year survival rate1.
RB score
Overall∗ Adenocarcinoma∗∗ Nonadenocarcinoma∗∗∗ p16-negative∗
Alive Dead Alive Dead Alive Dead Alive Dead
Positive 7 (21.9) 25 (61) 5 (18.5) 15 (62.5) 3 (42.8) 10 (58.8) 6 (20.0) 17 (70.8)
Negative 25 (78.1) 16 (39.0) 25 (81.5) 9 (37.5) 4 (57.1) 7 (41.2) 24 (80.0) 7 (29.2)
1The data presented in the table in format of “case number (% of the same column)”.
Fisher’s probability exact test (two tailed): ∗P<0.001, ∗∗P<0.05; ∗∗∗not done.
expression. In adenocarcinoma or p16INK4-negative tumors,
the positive RB1 expression was also associated with the
unfavorable outcomes (RR = 2.833, 95% CI: 1.532–5.239;
P<0.001; and RR = 3.273, 95% CI: 1.632–6.562, P<0.001,
resp.). Some RB1-negative tumors in which no trace of RB1
was detected (15%, 11/73) had unfavorable outcomes. Their
correlations to the outcomes were not statistically signiﬁcant
due to lack of enough samples (data not shown). Patients
with both p16+/RB1+ tumors were all dead (100%, 8/8)
in 5 years, which was much higher than p16+/RB1− (64%,
9/14) tumors, but a statistically signiﬁcant correlation was
not sought due to the low number of cases.
4. Discussion
In this study, we demonstrated that factors associated with
poor outcomes in stage I and II nonsquamous NSCLC
includednonadenocarcinoma,positiveexpressionofp16INK4
and RB1 by IHC, and with CNV of CDKN2A gene in the
tumor cells.
Consistent with previous reports, p16INK4 was unde-
tectable in the normal tissues or the stromal cells of the
tumor tissues. The absent expression of p16INK4 in the
tumor cells, however, might be caused by homozygous
loss of CDKN2A gene as demonstrated in this study or
hypermethylation of the CDKN2 p r o m o t e r sa ss e e ni no t h e r
tumor types [22, 23]. The causes of the overexpression in the
tumor cells might resulted from genetic abnormalities, viral
eﬀectoratumor-associatedmutantofCDKN2A[24–26].We
demonstrated that in NSCLC, 32% of the p16INK4-positive
cases was resulted from the increased copy numbers of
CDKN2A.TheHPVviraleﬀectwasruledoutbynegativeISH
results in this study. Therefore, studies for the mechanisms
that result in an upregulated p16INK4 expression should be
sought in the future.
The overexpression of p16INK4 p r o t e i ni nt u m o rc e l l si s
notuncommonﬁndings.Forexample,p16INK4 wasincreased
in multiple ovarian cancer cell lines as well as in 7 of
10 clinical ovarian cancer specimens [27]. Previous reports
also showed that p16INK4-positive prostate cancers were
associated with early relapse and relapse, its association to
an unfavorable prognosis in NSCLC is not known yet [28–
30]. The paradoxical p16INK4 positivity in NSCLC associated
to the poor outcome is demonstrated in this study though
interpretation needs to be cautious due to relatively small
numbers included.
Like p16INK4, loss of RB1 function by genetic deletion is
commonly seen to be an essential process of oncogenesis in
wide ranges of human malignancy, such as retinoblastoma,
breast cancer, and small cell carcinoma of the lungs. The
increased RB1 in tumor cells was puzzling but was observed
in colorectal carcinoma and bladder tumors [31, 32]. In this
study, we demonstrated that RB1 positivity in NSCLC was
often seen (43.8%) in NSCLC. Furthermore, we demon-
strated that its overexpression was signiﬁcantly associated
with the adverse outcomes. In addition, in those p16INK4-
negative or adenocarcinoma tumors, the RB1 status stratiﬁes
them into favorable and unfavorable groups.
Abundant functionally defective mutant protein might
be produced in the tumor cells, but their signiﬁcance to the
clinical outcomes is not clear yet [33, 34]. The signiﬁcance of
increased expression of functionally intact tumor suppressor
proteins such as p16 and RB1 in malignant cells remains
poorly understood but might be explained by the concept
of the cellular homeostasis in the cancer cells. For example,
the apoptosis that normally resulted from Myc overpro-
duction can be suppressed in tumor cells by oncogenic
mutations that stimulate survival signals or directly inhibit
the apoptotic machinery. Therefore, in order to couple with
the hyperproliferation stress, the tumor cells might increase
the production of cell-cycle inhibitory proteins such as
p16INK4 to suppress the G1/S transition. The tumor cells
with low proliferation might be more resistant to radiation
and chemotherapy. Furthermore, the roles of overexpressed
RB1 in suppressing the apoptosis might result in resistance
to therapeutic radiation or chemotherapy, too [35, 36].
In conclusion, we demonstrated that tumors with higher
expression of p16INK4 and RB1 were statistically signiﬁcantly
associated with unfavorable outcomes in patients with stage
I and II nonsquamous NSCLC. The stratiﬁcation of these
patients by proﬁling p16INK4 and RB1 protein expression in
the tumors might provide predictive biomarkers for cancer
prognosis. Further works to understand how these tumor
suppressor genes were abnormally upregulated, and their
roles in cancer homeostasis are needed to provide scientiﬁc
bases for the prevention interference.
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